HCV - Clinical Trials / Studies



•Roche Polymerase Inhibitor R1626 Demonstrates Antiviral Activity and Good Safety in Phase I Study  11/10/06
•Preclinical Study Shows ITMN-191 Plus Pegasys is Active against HCV In Vitro  11/10/06
•PegIntron plus Ribavirin in HCV Genotype 1 Patients with Slow Virological Response: Analysis of Early Enrollers in the SUCCESS Study  11/07/06
•Utility of Virological Response at Weeks 4 and 12 in the Prediction of SVR in Genotype 2/3 Patients: ACCELERATE Trial Results  11/07/06
•Consistent SVR Rates across All Weight Categories in the Canadian POWeR Program  11/07/06
•Risk Factors for Relapse in Patients with High Viral Load and Genotype 3 Hepatitis C in the WIN-R Trial  11/03/06
•HCV RNA Negativity after 12 Weeks of Therapy Is the Best Predictor of SVR in Re-Treatment of Non-Responders: The EPIC3 Program  11/03/06
•Response to PegIntron and Ribavirin in HCV Patients with Body Weight >125 kg: the WIN-R Trial  11/03/06
•In ACCELERATE Trial, Highest SVR Seen in Patients Who Received the Longest Duration of Therapy with Pegasys and the Highest Mean Dose of Ribavirin Based on Body Weight  11/03/06
•Positive Impact of Higher Ribavirin Doses and Longer Duration of Therapy with Pegasys plus Ribavirin in HIV/HCV Coinfected Patients: The PRESCO Trial  11/03/06
•PegIntron and Ribavirin Are Equally Effective and Well Tolerated in Patients >65 Years Old in Comparison to Other Age Groups: WIN-R Trial  11/03/06

 



Google_______________


 

 

 

 

 

 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka